As a pioneer in antiviral drug development, Gilead is leading the charge in
neglected & emerging viruses and pandemic preparedness.
View Our Pipeline
- Our Vision: Resilience at Scale
- A History of Innovation
Our Vision: Resilience at Scale
Gilead envisions a future where we are equipped with countermeasures against emerging viral threats before they escalate into global crises. We’re aiming to build a resilient framework that offers comprehensive protection and preparedness on a worldwide scale — grounded in science, collaboration and equitable access — to help safeguard global health and set new standards in pandemic readiness.
A History of Innovation
For more than three decades, Gilead has helped change the course of viral disease — delivering a cure for hepatitis C, transforming the management of hepatitis B, bringing the first treatment for hepatitis D to market in Europe, Great Britain, Switzerland, Australia and Canada. Gilead also introduced the first single-tablet treatment regimen for HIV. When COVID-19 emerged, we mobilized at speed to deliver the first approved antiviral treatment for the disease and rapidly scaled global access. This track record of turning breakthrough science into real world impact guides how we prepare for and respond to emerging viral threats today.
Our Impact
HCV patients cured with
Gilead-innovated therapies
of people worldwide living with HIV receive a Gilead-innovated
treatment regimen
people were treated globally with the first approved antiviral medicine for the treatment of COVID-19,
developed by Gilead
Preparing for Neglected and Emerging Viral Threats
We focus where the stakes are highest, aiming to tackle the most devastating diseases. This includes filoviruses such as Ebola and Marburg, flaviviruses like dengue, and other emerging threats.
When a threat emerges, we move together — mobilizing research, clinical, regulatory, quality, manufacturing and supply chain teams in parallel with public health partners to align on evidence, authorization and distribution as the science advances. Our strategy brings rigorous science together with field ready development, including the development of obeldesivir* — an investigational, oral broad spectrum antiviral designed to target conserved viral replication mechanisms. This work has potential to support outbreak settings from inpatient care to potential postexposure scenarios, helping protect communities faster.
We also partner to generate evidence and support response on the ground. We collaborate with the World Health Organization (WHO) on its pan-filovirus platform treatment protocol and have supported emergency responses by supplying investigational treatment for clinical evaluation and emergency use under local authorization.
*Obeldesivir is investigational and has not been approved by any regulatory authority.
Enabling Access for All
Access and equity are essential in a public health emergency. We design our antiviral supply chain for speed and reach — rapidly transferring technology, qualifying multiple suppliers and activating regional production to meet real time demand.
- Access from day one: Voluntary licensing enables supply in more than 120 low- and middle-income countries, supported by technology transfer and
on-the-ground technical assistance to accelerate partner production. - Partnered deployment: We work alongside ministries of health, the WHO and regional agencies on emergency authorizations, distribution and safety monitoring so treatments can reach people quickly and responsibly.
- Built-in reliability: Multisource supply, regional inventory placement and data-driven forecasting help ensure continuity through demand surges.
Preparedness is a shared mission. Our partners are essential to the communities we serve, and we look forward to our continued collaboration to help improve access to care by eliminating barriers and advancing education.
We’re members of the INTREPID Alliance — a consortium of innovative biopharmaceutical companies dedicated to accelerating the development of antiviral treatments to help protect the world ahead of future pandemics. We also support the 100 Days Mission
and have engaged with global health stakeholders on the WHO Pandemic Agreement
process to help strengthen preparedness and equitable access. Together, these collaborations help compress timelines from signal to solution and enable faster, more equitable access when outbreaks occur.
HIV
We’re pursuing advancements in HIV through scientific innovation and community partnerships.
Viral Hepatitis
Gilead researchers are transforming the lives of people living with hepatitis B, C and D through groundbreaking science.